TRVI

Trevi Therapeutics, Inc. [TRVI] Stock Forecast

Q: What is Trevi Therapeutics, Inc. stock symbol ?

Trevi Therapeutics, Inc. is a US stock, located in New haven of Ct and trading under the symbol TRVI

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

TRVI Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 192.68%

EPS has been decreasing for the past 3 quarters (Quarter statements)

Top 10 Correlated Stocks

TRVI

In the News

10:49 29 Sep 2023 TRVI

Trevi Therapeutics, Inc. (TRVI) Q2 2023 Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer Lisa Delfini - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Serge Belanger - Needham and Company Leland Gershell - Oppenheimer William Wood - B. Riley Securities Operator Good afternoon and welcome to the Trevi Therapeutics' Second Quarter 2023 Earnings Conference Call.

11:10 29 Sep 2023 TRVI

Trevi Therapeutics, Inc. (TRVI) Q4 2022 Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Jennifer Good - President & Chief Executive Officer Lisa Delfini - Chief Financial Officer David Clark - Chief Medical Officer Conference Call Participants Leland Gershell - Oppenheimer Nat Charoensook - SVB Securities Sean Kim - Jones Trading Mayank Mamtani - B. Riley Securities Operator Good afternoon and welcome to the Trevi Therapeutics Q4 and Year-End 2022 Earnings Conference Call.

07:30 29 Sep 2023 TRVI

Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023

Corporate presentation at 10:50 a.m. ET NEW HAVEN, Conn.

07:41 29 Sep 2023 TRVI

Trevi Therapeutics, Inc. (TRVI) Q3 2022 Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Jennifer Good - President and CEO Lisa Delfini - CFO Conference Call Participants Annabel Samimy - Stifel Serge Belanger - Needham & Company Operator Good afternoon, and welcome to the Trevi Therapeutics Q3 2022 Earnings Conference Call. [Operator Instructions] Please note, today's event is being recorded.

04:48 29 Sep 2023 TRVI

Andreas Halvorsen Enters Holding in Trevi Therapeutics

Andreas Halvorsen (Trades, Portfolio), a founding partner of Viking Global Investors LP, revealed in a Schedule 13G filing that he entered a new position in Trevi Therapeutics Inc. ( TRVI , Financial).

08:22 29 Sep 2023 TRVI

These Are The Five Best And Worst Performing Penny Stocks Of 2022 (So Far)

Penny stocks are shares that usually trade at $5 or less. These stocks are mostly of small companies that usually trade over-the-counter (OTC).

08:20 29 Sep 2023 TRVI

Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q2 2022 Results - Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Lisa Delfini – Chief Financial Officer Bill Forbes – Chief Development Officer Conference Call Participants Annabel Samimy – Stifel Serge Belanger – Needham & Company Leland Gershell – Oppenheimer Nathan Weinstein – Aegis Operator Good afternoon, and welcome to the Trevi Therapeutics Second Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

07:30 29 Sep 2023 TRVI

Trevi Therapeutics to Present at Upcoming August Conferences

NEW HAVEN, Conn. , Aug. 9, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced it will be presenting at the following investor and medical meeting conferences: Senior management at Trevi Therapeutics will be presenting at August investor and medical meeting conferences Stifel Biotech Executive Summer Summit (In-person) Date: Tuesday, August 16, 2022 Fireside chat presentation: Jennifer Good, President and CEO Time: 9:00 AM ET The fireside chat is an invitation-only event and will be available to attending participants.

05:41 29 Sep 2023 TRVI

Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022

Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.

02:00 29 Sep 2023 TRVI

How to Find Trending Penny Stocks in 2022

Tips for making a list of trending penny stocks in 2022 The post How to Find Trending Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

TRVI Financial details

Company Rating

Neutral

Market Cap

135.36M

Income

-27.32M

Revenue

Book val./share

0.96

Cash/share

0.95

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

08 Nov 2023

P/E

-8.22

Forward P/E

PEG

1.04

P/S

P/B

2.36

P/C

2.39

P/FCF

-4.38

Quick Ratio

19.99

Current Ratio

21.06

Debt / Equity

0.02

LT Debt / Equity

0.01

EPS (TTM)

-0.31

EPS next Y

EPS next Q

EPS this Y

-69.8%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

11.56%

SMA20

-3.98%

SMA50

-3.56%

SMA100

-34.24%

Inst Own

49.4%

Inst Trans

1.12%

ROA

-27%

ROE

-26%

ROC

-0.32%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

63.85M

Shs Float

24.68M

Target Price

52W Range

1.43-3.5

52W High

-24.17%

52W Low

+127.5%

RSI

53.95

Rel Volume

0.13

Avg Volume

176.54K

Volume

22.33K

Perf Week

4.84%

Perf Month

-3.6%

Perf Quarter

26.39%

Perf Half Y

26.39%

Beta

0.757735

Volatility

0.05%, 0.07%

Prev Close

1.56%

Price

2.275

Change

2.94%

TRVI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0	0	0	0	0
Net income per share	-2.29	-1.46	-1.81	-1.49	-0.45
Operating cash flow per share	-2.04	-1.29	-1.61	-1.27	-0.44
Free cash flow per share	-2.06	-1.3	-1.61	-1.27	-0.44
Cash per share	1.91	3.21	2.49	1.61	1.87
Book value per share	1.93	3.06	1.51	0.75	1.66
Tangible book value per share	1.93	3.06	1.51	0.75	1.66
Share holders equity per share	1.93	3.06	1.51	0.75	1.66
Interest debt per share	0.02	0.02	0.81	0.69	0.15
Market cap	70.74M	66.88M	43.7M	17.87M	124.57M
Enterprise value	53.57M	9.92M	12.91M	-4.33M	121.15M
P/E ratio	-3.44	-2.57	-1.33	-0.53	-4.27
Price to sales ratio	0	0	0	0	0
POCF ratio	-3.87	-2.9	-1.51	-0.62	-4.42
PFCF ratio	-3.83	-2.89	-1.51	-0.62	-4.4
P/B Ratio	4.09	1.23	1.6	1.05	1.16
PTB ratio	4.09	1.23	1.6	1.05	1.16
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-2.62	-0.37	-0.4	0.13	-4.05
EV to operating cash flow	-2.93	-0.43	-0.45	0.15	-4.3
EV to free cash flow	-2.9	-0.43	-0.44	0.15	-4.28
Earnings yield	-0.29	-0.39	-0.75	-1.9	-0.23
Free cash flow yield	-0.26	-0.35	-0.66	-1.62	-0.23
Debt to equity	0	0.01	0.52	0.86	0.09
Debt to assets	0	0.01	0.3	0.38	0.07
Net debt to EBITDA	0.84	2.14	0.95	0.68	0.11
Current ratio	7.02	11.45	8.33	2.98	9.15
Interest coverage	-105.79	0	-71.25	-27.02	-38.34
Income quality	0.89	0.89	0.89	0.85	0.97
Dividend Yield	0	0.03	0	0	0
Payout ratio	0	-0.09	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	0	0	0	0.01
Capex to revenue	0	0	0	0	0
Capex to depreciation	-6.87	-0.23	-0.68	0	-3.7
Stock based compensation to revenue	0	0	0	0	0
Graham number	9.98	10.03	7.85	5	4.11
ROIC	-1.06	-0.48	-0.78	-1.02	-0.26
Return on tangible assets	-1	-0.43	-0.7	-0.88	-0.24
Graham Net	1.65	2.98	1.43	0.68	1.63
Working capital	16.11M	54.35M	40.71M	25.23M	109.22M
Tangible asset value	17.31M	54.55M	27.28M	17.08M	107.46M
Net current asset value	15.61M	54.1M	26.42M	16.56M	107.06M
Invested capital	0	0.01	0.52	0.86	0.09
Average receivables	122.5K	371K	411.5K	253K	120.5K
Average payables	570K	1.1M	1.81M	2.43M	2.85M
Average inventory	729.5K	1.5M	1.25M	447.5K	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-1.19	-0.48	-1.2	-1.99	-0.27
Capex per share	-0.02	0	0	0	0

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
Revenue per share	0	0	0	0	0
Net income per share	-0.14	-0.12	-0.06	-0.06	-0.07
Operating cash flow per share	-0.1	-0.12	-0.06	-0.08	-0.1
Free cash flow per share	-0.1	-0.12	-0.07	-0.08	-0.1
Cash per share	1.31	1.82	1.23	1.13	0.95
Book value per share	1.02	1.6	1.1	1.03	0.96
Tangible book value per share	1.02	1.6	1.1	1.03	0.96
Share holders equity per share	1.02	1.6	1.1	1.03	0.96
Interest debt per share	0.21	0.16	0.1	0.09	0.02
Market cap	167.31M	106.1M	189.4M	182.43M	235.89M
Enterprise value	155.14M	50.39M	185.99M	179.79M	223.61M
P/E ratio	-5.19	-3.21	-8.6	-7.13	-8.25
Price to sales ratio	0	0	0	0	0
POCF ratio	-27.09	-12.37	-29.92	-22.26	-23.89
PFCF ratio	-27.09	-12.37	-29.38	-22.1	-23.79
P/B Ratio	2.76	0.97	1.76	1.79	2.48
PTB ratio	2.76	0.97	1.76	1.79	2.48
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-20.09	-6.25	-27.94	-23.77	-31.99
EV to operating cash flow	-25.12	-5.88	-29.38	-21.93	-22.64
EV to free cash flow	-25.12	-5.88	-28.85	-21.78	-22.55
Earnings yield	-0.05	-0.08	-0.03	-0.04	-0.03
Free cash flow yield	-0.04	-0.08	-0.03	-0.05	-0.04
Debt to equity	0.21	0.1	0.09	0.09	0.02
Debt to assets	0.15	0.08	0.07	0.08	0.01
Net debt to EBITDA	1.58	6.91	0.51	0.35	1.76
Current ratio	5.18	8.7	9.15	8.65	21.06
Interest coverage	-40.94	-41.4	-33.28	-43.97	-55.51
Income quality	0.77	1.04	1.15	1.28	1.38
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0.02	0.01	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	-7.73	-3	-1.18
Stock based compensation to revenue	0	0	0	0	0
Graham number	1.76	2.08	1.18	1.23	1.25
ROIC	-0.11	-0.07	-0.06	-0.07	-0.09
Return on tangible assets	-0.1	-0.06	-0.04	-0.06	-0.07
Graham Net	0.96	1.56	1.07	0.98	0.89
Working capital	64.45M	112.68M	109.22M	101M	94.5M
Tangible asset value	60.52M	109.9M	107.46M	101.73M	95.07M
Net current asset value	58.99M	108.86M	107.06M	99.73M	93.31M
Invested capital	0.21	0.1	0.09	0.09	0.02
Average receivables	0	0	0	0	0
Average payables	2.84M	3.14M	2.6M	2.42M	1.67M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.13	-0.08	-0.05	-0.06	-0.08
Capex per share	0	0	0	0	0

TRVI Frequently Asked Questions

What is Trevi Therapeutics, Inc. stock symbol ?

Trevi Therapeutics, Inc. is a US stock , located in New haven of Ct and trading under the symbol TRVI

Is Trevi Therapeutics, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $12. The lowest prediction is $12 and the highest is $12

What is TRVI stock prediction ?

What is Trevi Therapeutics, Inc. stock quote today ?

Trevi Therapeutics, Inc. stock price is $2.275 today.

Is Trevi Therapeutics, Inc. stock public?

Yes, Trevi Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap

MSF.DE

M&M.NS

RILYO

Company Profile

Volume Average 176.54K
Market Capitalization 135.36M
Employee 30
CEO Ms. Jennifer L. Good
Headquarters New Haven,CT,US
IPO Date 2019-05-07
Website https://www.trevitherapeutics.com

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.